查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1834173

藥物濫用檢測市場（按樣本類型、檢測技術、最終用戶和藥物小組分類）—2025-2032 年全球預測

Drug of Abuse Testing Market by Sample Type, Test Technology, End User, Drug Panel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，藥物濫用檢測市場規模將成長至 33.4 億美元，複合年成長率為 7.49%。

主要市場統計數據
基準年2024年 18.7億美元
預計2025年 20.1億美元
預測年份：2032年 33.4億美元
複合年成長率（%） 7.49%

對當前藥物濫用檢測環境的權威說明，重點介紹不斷變化的使用模式、跨部門需求和實際操作挑戰

藥物濫用檢測是臨床實踐、法醫學、公共衛生監測和職場安全的交叉領域。過去十年，物質的多樣化、使用模式的改變以及監管審查的加強，迫使實驗室和採購團隊採用更準確、更快速、更全面的分析方法。同時，最終用戶越來越需要能夠在診斷準確性、週轉時間和成本效益之間取得平衡的解決方案，這迫使技術供應商在檢測方法、儀器和數據管理方面不斷創新。

隨著相關人員的不斷適應，生態系統正在從傳統的醫院和法醫學環境擴展到懲教機構、職業健康服務提供者和以地區為基礎篩檢計畫。這種多樣化影響著檢體類型、檢測試劑盒以及篩檢和確認方法的相對組合。因此，實驗室必須重新思考工作流程設計、品質保證和供應鏈彈性，而監管機構也必須更新其框架，以應對新興合成藥物和新型精神活性物質。在此背景下，對於尋求使能力與不斷變化的需求模式和合規期望保持一致的領導者來說，了解樣本採集選擇、分析平台和最終用戶需求之間的相互關係至關重要。

技術創新、多樣化的樣本應用和數位整合如何重塑測試的分析方法和相關人員的期望

由於分析化學的進步、對照護現場和快速確認工作流程的需求不斷成長，以及標靶藥物組合類型的擴展，濫用藥物檢測領域正在發生重大變化。高解析度和串聯式質譜質譜儀已從專業參考實驗室遷移到更廣泛的臨床和法醫學環境中，從而能夠更可靠地檢測低濃度代謝物和新型合成化合物。同時，免疫測量平台仍然是經濟高效的篩檢工具，但現在通常採用混合工作流程，其中層析法確認補充初步篩檢並減少假陽性和假陰性。

同時，樣本類型的創新正在改變下游物流和檢測視窗。頭髮分析為回顧性調查提供了長期暴露的寶貴見解，而口腔液體分析則提供了一種侵入性較小的現場替代方法，與近期使用情況密切相關。尿液檢查由於其既定的方案和廣泛的檢驗歷史，仍然是許多計畫的支柱。實驗室資訊管理系統和連接解決方案簡化了結果報告，支援監管鏈要求，並與電子健康記錄和懲教管理系統整合。隨著政策框架不斷發展以適應新物質和隱私考慮，相關人員必須在技術機會與道德、法律和營運約束之間取得平衡，以確保採用這些技術能夠增強分析的嚴謹性和相關人員的信任。

評估近期美國關稅對實驗室和供應商採購、供應鏈彈性和業務連續性的影響

美國近期的關稅措施和貿易調整對藥物濫用檢測供應鏈產生了切實的影響，尤其對依賴國際採購設備、耗材和試劑的實驗室和供應商而言。進口關稅的提高導致層析法系統、質譜儀和專用耗材的到岸成本上升，迫使採購團隊重新評估供應商合約、維護協議和總擁有成本的計算。這促使一些機構加快庫存規劃，並考慮對關鍵試劑進行策略性儲備，以維持高通量檢測環境的連續性。

此外，關稅政策也鼓勵供應商實現產品組合多元化和在地採購策略。為了降低買家的成本敏感性，儀器製造商和試劑供應商正在評估各種方案，例如重新配置生產佈局、調整零件採購以及提供更靈活的租賃和服務模式。這種轉變將對維修週期、保固範圍和技術支援管道產生下游影響，尤其對於偏遠和服務欠缺地區的機構。重要的是，面對成本動態，合規義務不會放鬆。實驗室必須持續滿足驗證和認證標準，這可能會使快速更換供應商變得複雜。因此，決策者應優先考慮供應鏈透明度、合約保障措施和緊急時應對計畫，以維護分析的完整性，同時應對關稅主導的市場動態引起的成本波動。

以細分市場主導的觀點，揭示樣本類型、分析平台、最終用戶需求和麵板配置如何相互作用，從而影響操作選擇

細分市場層面的動態揭示了需求促進因素和技術要求，這些因素因樣本類型、分析技術、最終用戶和樣本組配置而異。就樣本類型而言，頭髮分析適用於回顧性暴露評估，並且往往更傾向於法醫學和矯正應用，因為這些應用優先考慮更寬的檢測視窗。另一方面，口腔液分析適用於即時篩檢，這種篩檢需要微創採集並與近期攝取量進行關聯。尿液檢查由於其標準化的流程以及在職業和臨床環境中的廣泛接受，在臨床實驗室和醫院中保持主導地位。

從檢測技術來看，免疫測量因其操作簡單、單次檢測成本低而仍適用於高性能篩檢，而層析法法則對於某些確認性工作流程至關重要。在層析法中，氣相層析質譜法 (GC-MS) 可對揮發性和熱穩定性化合物進行可靠的分析，而液相層析法質譜法 (LC-MS) 已成為層析法廣泛分析的首選方法，包括極性和熱不穩定化合物。此外，液相層析法法本身又分為串聯式質譜質譜配置（可實現標靶定量）和 LC-QToF 平台（可實現新型化合物的高解析度篩檢和非標靶發現）。臨床實驗室和醫院優先考慮通量、認證以及與患者記錄的整合；法醫學實驗室優先考慮證據保管鍊和法律情況下的可辯護性；懲教機構更傾向於穩健且易於管理的工作流程；專業實驗室可能需要可自訂的檢測菜單。最後，藥物小組的組成決定了採購和營運規劃。客製化的擴展面板可滿足複雜的臨床研究和法醫學調查的需求，而固定的 5 和 10 面板選項則平衡了整體性和成本效益，可滿足許多日常職場和路邊篩檢要求。

將監管、基礎設施和滲透因素與全球市場的不同發展和採用路徑聯繫起來的區域分析

區域差異反映了管理體制、醫療保健基礎設施成熟度和採用模式，這些因素共同塑造了採用路徑和服務交付模式。在美洲，刑事鑑定和職場檢測框架相對成熟，支援強大的參考實驗室網路、多樣化的檢測組合以及整合的報告基礎設施。隨著相關人員響應公共衛生舉措和雇主主導的合規計劃，對高性能儀器和監管鏈系統的投資仍然是優先事項。

在歐洲、中東和非洲，監管協調工作與巨大的國家和地區差異並存，導致先進儀器和確認性檢測實踐的採用曲線各不相同。一些市場強調嚴格的認證和法律倡導，而其他市場則支持對層析法確認性檢測的需求，還有一些市場優先考慮可在分散的醫療保健系統中部署的可擴展篩檢解決方案。在亞太地區，臨床和刑事鑑定實驗室的快速現代化，加上公共衛生監測的不斷擴大，正在推動人們對高解析度質譜和分散式樣本採集策略的興趣。該地區還提供了本地化供應鏈和開發服務模式的機會，以滿足都市區地區不同的物流和培訓需求。在整個地區，互通性、勞動力能力和監管一致性仍然是擴展可靠檢測服務的關鍵推動因素。

考慮決定公司如何獲得價值的競爭優勢和服務差異化，包括儀器可靠性、分析深度和數位化準備度

在分析平台日益複雜的時代，競爭動態強調整合服務、可靠的售後支援和協作研究夥伴關係。領先的儀器製造商在分析性能、使用者介面設計和認證耗材生態系統方面展開競爭，這些生態系統旨在減少差異性並簡化驗證。對於那些面臨人員限制且需要可預測正常執行時間以實現高通量操作的實驗室來說，能夠提供完善的培訓、快速響應的技術支援和靈活服務協議的供應商正日益受到青睞。

與此同時，診斷和檢測服務供應商正透過專業的檢測方法開發、可自訂的試劑盒配置以及針對臨床、法醫學和矯正用例的快速交付來脫穎而出。儀器供應商和檢測方法開發商之間的開發合作正在促成捆綁解決方案，從而降低採用先進方法的門檻。此外，提供實驗室資訊管理、結果解讀支援以及與醫療保健系統連接的軟體和資訊學公司正透過提高工作流程效率和確保符合報告標準發揮日益重要的戰略作用。總體而言，那些將卓越的儀器與生命週期支援、檢測深度和數位化賦能相結合的公司，最有能力滿足不同最終用戶不斷變化的需求。

產業領導者可採取的策略重點，以加強測試可靠性、供應彈性、勞動力和監管參與

藥物濫用檢測生態系統的領導者應優先考慮三項並行行動，以增強韌性並抓住新機會。首先，投資模組化混合檢測架構，該架構將免疫測量篩檢與層析法確認相結合，並融合集中式和分散式樣品工作流程。這種方法使組織能夠最佳化成本和交付時間，同時保持法醫學和臨床應用的分析防禦能力。其次，透過多元化供應商關係、協商延長支援期以及建立關鍵耗材的緊急庫存，提高供應鏈透明度和合約彈性。這些措施可以減少進口關稅波動和物流中斷帶來的風險。

第三，我們將透過投資實驗室資訊學和有針對性的培訓計畫來提升員工能力和數位化水平，從而簡化報告、品管和法規遵循流程。加強技術能力和數據工作流程將使各機構能夠擴展先進的檢測模式，並將其整合到更廣泛的臨床和公共衛生計劃中。最後，我們將積極與政策制定者和標準組織合作，針對新興物質和新型樣本類型製定實用的、循證的指南。這些綜合行動將在不斷變化的政策和技術環境中，為營運穩定性、卓越的分析能力和靈活的商業策略奠定基礎。

透明、多方法的調查方法結合了相關人員訪談、技術檢驗證據和監管審查，支持可行的建議

本執行摘要所依據的研究結合了對實驗室主任、採購經理和法醫學專家的初步訪談，以及對近期同行評審文獻、監管指南和公共衛生監測報告的二次分析。調查方法的嚴謹性源自於將定性洞察與透過多項獨立檢驗研究記錄的檢測技術和儀器性能屬性進行三角檢驗。我們還審查了案例研究和供應商能力評估，以確定反覆出現的營運主題，例如工作流程整合、維護模型和培訓需求。

在整個分析過程中，我們特別注重確保可重複性和透明度。證據的權重由來源類型和研究納入標準決定，敏感性檢查則用於處理供應商提供的資訊可能造成的偏倚。當監管解釋有爭議時，評估依據公開的政策文件和專業協會的共識聲明。這種混合方法有助於得出平衡的結論，同時考慮臨床環境的異質性和技術變革的步伐。

最後綜合總結了綜合技術採用、供應鏈規劃和勞動力發展將如何決定未來檢查的可靠性和影響力。

總而言之，藥物濫用檢測領域正處於關鍵時刻，技術能力、政策轉變和最終用戶的多樣性正在匯聚，重新定義操作規範。實驗室和供應商既面臨著整合複雜分析平台的挑戰，也面臨著提供更可靠結果以更好地服務臨床護理、法醫學流程和公共的機會。供應鏈壓力和不斷變化的貿易政策要求我們制定積極的採購和應急計劃，而地區差異則要求我們制定因地制宜的部署策略。

展望未來，那些採用混合檢測模式、投資於員工團隊建設和數位化工作流程，並在整個價值鏈上建立合作夥伴關係關係的組織將獲得成功。透過將技術投資與樣本類型、最終用戶需求和監管期望等實際因素相結合，相關人員可以提高檢測的可靠性，並確保結果在臨床、法律和專業領域具有可操作性。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 臨床環境中擴大採用靈敏質譜法進行全面的藥物篩檢
  • 擴大分散式口腔液體即時檢測，以便在偏遠地區快速檢測合成鴉片類藥物
  • 將人工智慧驅動的預測分析整合到您的實驗室中，以解釋藥物代謝物並減少假陽性
  • SAMHSA 認證合規監管壓力不斷加大，推動標準化尿液免疫檢測面板的採用
  • 家用多功能檢測套組的普及使得雇主能夠遠端進行篩檢前和持續的篩檢。
  • 開發多重 LC-MS/MS 分析方法，用於同時定量新型合成大麻素和鴉片類藥物
  • 加強遠端醫療提供者和臨床實驗室之間的合作，以促進遠距藥物測試和監測項目
  • 在法醫學和臨床應用中，對毛囊分析以檢測長期藥物使用模式的需求日益成長。

第6章 2025年美國關稅的累積影響

第7章 人工智慧的累積影響，2025年

8. 藥物濫用檢測市場（依樣本類型）

  • 頭髮
  • 口腔液體
  • 尿

9. 藥物濫用檢測市場（依檢測技術）

  • 層析法
    • GC-MS
    • Lc-Ms
      • Lc-Ms/Ms
      • Lc-Qtof
  • 免疫檢測

第 10 章。藥物濫用檢測市場（按最終用戶）

  • 臨床實驗室
  • 懲教設施
  • 法醫學實驗室
  • 醫院

第 11 章。藥物濫用檢測市場（按藥物小組）

  • 可自訂面板
  • 放大面板
  • 5個面板
  • 10個面板

12. 藥物濫用檢測市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章藥物濫用檢測市場（按類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國濫用藥物檢測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Thermo Fisher Scientific Inc.
    • Roche Holding AG
    • Abbott Laboratories
    • Siemens Healthineers AG
    • Danaher Corporation
    • Bio-Rad Laboratories, Inc.
    • Hologic, Inc.
    • PerkinElmer, Inc.
    • Sysmex Corporation
    • Becton, Dickinson and Company
Product Code: MRR-4348D129FA91

The Drug of Abuse Testing Market is projected to grow by USD 3.34 billion at a CAGR of 7.49% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.87 billion
Estimated Year [2025] USD 2.01 billion
Forecast Year [2032] USD 3.34 billion
CAGR (%) 7.49%

An authoritative orientation to the current drug of abuse testing environment highlighting evolving use patterns, cross-sector demands, and practical operational challenges

Drug of abuse testing sits at the intersection of clinical practice, forensic science, public health surveillance, and workplace safety. Over the past decade, escalating substance diversity, shifting patterns of use, and intensified regulatory scrutiny have placed testing laboratories and procurement teams under pressure to adopt more precise, rapid, and comprehensive analytical approaches. Meanwhile, end users increasingly demand solutions that balance diagnostic accuracy, turnaround time, and cost-efficiency, compelling technology providers to innovate across assay formats, instrumentation, and data management.

As stakeholders adapt, the ecosystem has expanded beyond traditional hospital and forensic settings to include correctional facilities, occupational health providers, and community-based screening programs. This diversification has implications for sample types, testing panels, and the relative mix of screening versus confirmatory methods. Consequently, laboratories must reconsider workflow design, quality assurance, and supply chain resilience while regulators update frameworks to address emerging synthetic drugs and novel psychoactive substances. In this context, understanding the interplay among sample collection choices, analytical platforms, and end-user requirements is essential for leaders aiming to align capabilities with evolving demand patterns and compliance expectations.

How technological breakthroughs, diversified sample applications, and digital integration are reshaping analytical approaches and stakeholder expectations in testing

The landscape of drug of abuse testing is undergoing transformative shifts driven by advancements in analytical chemistry, growing demand for point-of-care and rapid-confirmation workflows, and an expanding palette of targeted drug panels. High-resolution mass spectrometry and tandem mass spectrometry have migrated from specialized reference laboratories into broader clinical and forensic settings, enabling detection of low-concentration metabolites and emerging synthetic compounds with greater confidence. At the same time, immunoassay platforms continue to serve as cost-effective screening tools, but they now frequently operate in hybrid workflows where chromatographic confirmation complements initial screening to mitigate false positives and negatives.

Concurrently, sample-type innovation is changing downstream logistics and detection windows. Hair analysis offers long-term exposure insights that are valuable for retrospective investigations, while oral fluid presents a less invasive, on-site alternative that correlates well with recent use. Urine testing remains the backbone of many programs due to established protocols and extensive validation histories. These shifts also intersect with digital transformation: laboratory information management systems and connectivity solutions streamline result reporting, support chain-of-custody requirements, and integrate with electronic health records and corrections management systems. As policy frameworks evolve to address novel substances and privacy considerations, stakeholders must balance technological opportunity with ethical, legal, and operational constraints, ensuring that adoption enhances both analytical rigor and stakeholder trust.

Assessing how recent United States tariff measures are influencing procurement, supply chain resilience, and operational continuity for laboratories and vendors

Recent tariff actions and trade policy recalibrations in the United States are creating tangible implications for the drug of abuse testing supply chain, particularly for laboratories and vendors that rely on internationally sourced instrumentation, consumables, and reagents. Increased import duties elevate landed costs for chromatography systems, mass spectrometers, and specialized disposables, prompting procurement teams to reassess vendor agreements, maintenance contracts, and total cost of ownership calculations. In response, some organizations are accelerating inventory planning and exploring strategic stockpiling of critical reagents to maintain continuity in high-throughput testing environments.

Moreover, the tariffs are encouraging diversification of supplier portfolios and localized sourcing strategies. Instrument manufacturers and reagent suppliers are evaluating options to reconfigure manufacturing footprints, adjust component sourcing, or offer more flexible leasing and service models to mitigate buyer cost sensitivity. This shift has downstream effects on maintenance turnarounds, warranty coverage, and technical support channels, especially for facilities in remote or underserved regions. Importantly, regulatory compliance obligations do not relax in the face of cost pressures; laboratories must continue to satisfy validation and accreditation standards, which can complicate rapid vendor switching. Therefore, decision-makers should prioritize supply chain transparency, contractual safeguards, and contingency planning to preserve analytical integrity while managing cost volatility induced by tariff-driven market dynamics.

Segment-driven perspectives illuminating how sample types, analytical platforms, end-user requirements, and panel composition interact to shape operational choices

Segment-level dynamics reveal differentiated demand drivers and technical requirements across sample types, analytical technologies, end users, and panel configurations. When considering sample type, hair analysis caters to retrospective exposure assessment and tends to attract forensic and correctional use cases that prioritize extended detection windows, while oral fluid appeals to on-site screening contexts that require minimally invasive collection and correlation with recent consumption. Urine testing maintains prominence across clinical laboratories and hospitals because of standardized procedures and broad acceptance in occupational and clinical settings.

Turning to test technology, immunoassay methods retain relevance for high-throughput screening due to their operational simplicity and lower per-test cost, yet chromatography-based approaches are essential for specific confirmation workflows. Within chromatography, gas chromatography-mass spectrometry provides reliable analysis for volatile and thermally stable compounds, whereas liquid chromatography-mass spectrometry has emerged as the preferred modality for a broader array of polar and thermally labile analytes. Moreover, the liquid chromatography category itself bifurcates into tandem mass spectrometry configurations that deliver targeted quantitation and LC-QToF platforms that enable high-resolution screening and untargeted discovery of novel compounds. End-user segmentation also influences technology choices and service models: clinical laboratories and hospitals emphasize throughput, accreditation, and integration with patient records; forensic labs prioritize chain-of-custody and defensibility in legal contexts; correctional facilities favor rugged, easy-to-administer workflows; and specialized laboratories may require customizable testing menus. Finally, drug panel configuration shapes procurement and operational planning: customized and expanded panels meet the needs of complex clinical and forensic investigations, while fixed five- and ten-panel options address many routine workplace and roadside screening requirements, balancing comprehensiveness with cost-effectiveness.

A regional analysis that connects regulatory, infrastructural, and prevalence factors to differentiated deployment and adoption pathways across global markets

Regional differentiation reflects regulatory regimes, healthcare infrastructure maturity, and prevalence patterns that collectively shape adoption pathways and service delivery models. In the Americas, forensic and workplace testing frameworks are relatively mature, supporting a robust network of reference laboratories, diversified assay portfolios, and integrated reporting infrastructures. Investment in high-throughput instrumentation and chain-of-custody systems remains a priority as stakeholders respond to both public health initiatives and employer-driven compliance programs.

In Europe, the Middle East, and Africa region, regulatory harmonization efforts coexist with significant heterogeneity across jurisdictions, producing varied adoption curves for advanced instrumentation and confirmatory testing practices. Some markets emphasize stringent accreditation and legal defensibility, which supports demand for chromatography-based confirmation, while others prioritize scalable screening solutions that can be deployed across fragmented healthcare systems. In the Asia-Pacific region, rapid modernization of clinical and forensic laboratories, coupled with expanding public health surveillance, is driving interest in both high-resolution mass spectrometry and decentralized sample collection strategies. This region also presents opportunities to localize supply chains and develop service models that address diverse logistical and training needs across urban and rural settings. Across all regions, interoperability, workforce competency, and regulatory alignment remain critical enablers for scaling reliable testing services.

Insights into competitive strengths and service differentiation that determine how companies capture value across instrument reliability, assay depth, and digital enablement

Competitive dynamics in the era of sophisticated analytical platforms place a premium on integrated service offerings, reliable post-sale support, and collaborative research partnerships. Leading instrument manufacturers compete on analytical performance, user interface design, and the ecosystem of certified consumables that reduce variability and simplify validation. Vendors that provide robust training, rapid technical support, and flexible service contracts gain traction among laboratories that face staffing constraints and need predictable uptime for high-throughput operations.

At the same time, diagnostic and laboratory services providers differentiate through specialized assay development, customizable panel configurations, and fast turnarounds tailored to clinical, forensic, and correctional use cases. Collaborations between instrument vendors and assay developers are enabling bundled solutions that lower barriers to adopting advanced methodologies. Additionally, software and informatics companies that offer laboratory information management, result interpretation aids, and connectivity to health systems play an increasingly strategic role by improving workflow efficiency and ensuring compliance with reporting standards. Overall, companies that combine instrument excellence with lifecycle support, assay depth, and digital enablement are best positioned to serve the evolving needs of diverse end users.

Actionable strategic priorities for industry leaders to enhance testing reliability, supply resilience, workforce capability, and regulatory engagement

Leaders in the drug of abuse testing ecosystem should prioritize three parallel actions to strengthen resilience and capture emerging opportunities. First, invest in modular, hybrid testing architectures that combine immunoassay screening with chromatography-based confirmation and incorporate both centralized and decentralized sample workflows. This approach allows organizations to optimize cost and turnaround time while maintaining analytical defensibility for forensic and clinical applications. Second, enhance supply chain transparency and contractual flexibility by diversifying supplier relationships, negotiating extended support terms, and building contingency inventories for critical consumables. Such measures mitigate exposure to import duty fluctuations and logistical disruptions.

Third, develop workforce capability and digital proficiency through targeted training programs and investments in laboratory informatics that streamline reporting, quality management, and regulatory compliance. By strengthening technical competencies and data workflows, organizations can scale advanced testing modalities and integrate them into broader clinical and public health initiatives. Finally, engage proactively with policymakers and standard-setting bodies to shape practical, evidence-based guidelines for emerging substances and novel sample types. Taken together, these actions create a foundation for operational stability, analytical excellence, and adaptive commercial strategies in a shifting policy and technological environment.

A transparent, multi-method research approach combining stakeholder interviews, technical validation evidence, and regulatory review to underpin practical recommendations

The research underpinning this executive summary synthesizes primary interviews with laboratory directors, procurement managers, and forensic specialists together with secondary analysis of recent peer-reviewed literature, regulatory guidance, and public health surveillance reports. Methodological rigor derives from triangulating qualitative insights with documented performance attributes of assay technologies and instrumentation across multiple independent validation studies. Case examples and vendor capability assessments were reviewed to identify recurring operational themes, such as workflow integration, maintenance models, and training needs.

Throughout the analysis, particular attention was paid to ensuring reproducibility and transparency: source types and study selection criteria guided evidence weighting, and sensitivity checks addressed potential biases stemming from vendor-provided information. Where regulatory interpretations were discussed, the assessment relied on publicly available policy documents and consensus statements from professional societies. This blended approach supports balanced conclusions while acknowledging the heterogeneity of practice environments and the pace of technological change.

Concluding synthesis on how integrated technological adoption, supply chain planning, and workforce development will determine future testing reliability and impact

In summary, the drug of abuse testing domain is at a pivotal moment where technological capability, policy shifts, and end-user diversity converge to redefine operational norms. Laboratories and vendors face both the challenge of integrating sophisticated analytical platforms and the opportunity to deliver higher-confidence results that better serve clinical care, forensic processes, and public safety. Supply chain pressures and changing trade policies require proactive procurement and contingency planning, while regional differences demand context-sensitive deployment strategies.

Moving forward, success will favor organizations that adopt hybrid testing models, invest in workforce development and digital workflows, and build collaborative partnerships across the value chain. By aligning technological investments with practical considerations around sample types, end-user needs, and regulatory expectations, stakeholders can enhance testing reliability and ensure that results remain actionable in clinical, legal, and occupational contexts.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of high-sensitivity mass spectrometry for comprehensive drug screening in clinical settings
  • 5.2. Expansion of decentralized point-of-care oral fluid testing for rapid detection of synthetic opioids at remote sites
  • 5.3. Integration of AI-driven predictive analytics in laboratories to interpret drug metabolites and reduce false positives
  • 5.4. Growing regulatory pressure for SAMHSA certification compliance driving adoption of standardized urine immunoassay panels
  • 5.5. Surge in at-home multi-analyte test kits enabling employers to conduct remote pre-employment and ongoing screening
  • 5.6. Development of multiplexed LC-MS/MS assays for simultaneous quantification of emerging synthetic cannabinoids and opioids
  • 5.7. Increasing collaboration between telehealth providers and clinical labs to facilitate remote drug testing and monitoring programs
  • 5.8. Rising demand for hair follicle analysis to detect long-term substance use patterns in forensic and clinical applications

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drug of Abuse Testing Market, by Sample Type

  • 8.1. Hair
  • 8.2. Oral Fluid
  • 8.3. Urine

9. Drug of Abuse Testing Market, by Test Technology

  • 9.1. Chromatography
    • 9.1.1. Gc-Ms
    • 9.1.2. Lc-Ms
      • 9.1.2.1. Lc-Ms/Ms
      • 9.1.2.2. Lc-Qtof
  • 9.2. Immunoassay

10. Drug of Abuse Testing Market, by End User

  • 10.1. Clinical Laboratory
  • 10.2. Correctional Facility
  • 10.3. Forensic Laboratory
  • 10.4. Hospital

11. Drug of Abuse Testing Market, by Drug Panel

  • 11.1. Customized Panel
  • 11.2. Expanded Panel
  • 11.3. Five Panel
  • 11.4. Ten Panel

12. Drug of Abuse Testing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Drug of Abuse Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Drug of Abuse Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Thermo Fisher Scientific Inc.
    • 15.3.2. Roche Holding AG
    • 15.3.3. Abbott Laboratories
    • 15.3.4. Siemens Healthineers AG
    • 15.3.5. Danaher Corporation
    • 15.3.6. Bio-Rad Laboratories, Inc.
    • 15.3.7. Hologic, Inc.
    • 15.3.8. PerkinElmer, Inc.
    • 15.3.9. Sysmex Corporation
    • 15.3.10. Becton, Dickinson and Company

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. DRUG OF ABUSE TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. DRUG OF ABUSE TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DRUG OF ABUSE TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY HAIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY HAIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY HAIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY HAIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY HAIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY HAIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY ORAL FLUID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY ORAL FLUID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY ORAL FLUID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY ORAL FLUID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY ORAL FLUID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY ORAL FLUID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY URINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY URINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY URINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY URINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY URINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY GC-MS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY GC-MS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY GC-MS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY GC-MS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY GC-MS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY GC-MS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS/MS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS/MS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS/MS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS/MS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS/MS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS/MS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-QTOF, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-QTOF, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-QTOF, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-QTOF, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-QTOF, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-QTOF, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CLINICAL LABORATORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CLINICAL LABORATORY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CLINICAL LABORATORY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CLINICAL LABORATORY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CLINICAL LABORATORY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CLINICAL LABORATORY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CORRECTIONAL FACILITY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CORRECTIONAL FACILITY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CORRECTIONAL FACILITY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CORRECTIONAL FACILITY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CORRECTIONAL FACILITY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CORRECTIONAL FACILITY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY FORENSIC LABORATORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY FORENSIC LABORATORY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY FORENSIC LABORATORY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY FORENSIC LABORATORY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY FORENSIC LABORATORY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY FORENSIC LABORATORY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CUSTOMIZED PANEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CUSTOMIZED PANEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CUSTOMIZED PANEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CUSTOMIZED PANEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CUSTOMIZED PANEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CUSTOMIZED PANEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY EXPANDED PANEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY EXPANDED PANEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY EXPANDED PANEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY EXPANDED PANEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY EXPANDED PANEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY EXPANDED PANEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY FIVE PANEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY FIVE PANEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY FIVE PANEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY FIVE PANEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY FIVE PANEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY FIVE PANEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY TEN PANEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY TEN PANEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY TEN PANEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY TEN PANEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY TEN PANEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY TEN PANEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 123. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 125. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 127. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 129. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2025-2032 (USD MILLION)
  • TABLE 131. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 133. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2025-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 140. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 142. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2024 (USD MILLION)
  • TABLE 144. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2025-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 146. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2025-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 154. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 156. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2024 (USD MILLION)
  • TABLE 158. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2025-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2024 (USD MILLION)
  • TABLE 162. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2025-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 196. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 198. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2024 (USD MILLION)
  • TABLE 200. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2025-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2025-2032 (USD MILLION)
  • TABLE 205. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 210. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 211. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 212. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 213. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2024 (USD MILLION)
  • TABLE 214. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2025-2032 (USD MILLION)
  • TABLE 215. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2024 (USD MILLION)
  • TABLE 218. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2025-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2024 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2025-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 240. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 241. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 242. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 243. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2024 (USD MILLION)
  • TABLE 244. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2025-2032 (USD MILLION)
  • TABLE 245. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2025-2032 (USD MILLION)
  • TABLE 249. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 254. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 255. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 256. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 257. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2024 (USD MILLION)
  • TABLE 258. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2025-2032 (USD MILLION)
  • TABLE 259. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2024 (USD MILLION)
  • TABLE 262. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2025-2032 (USD MILLION)
  • TABLE 277. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 282. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 283. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 284. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 285. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2024 (USD MILLION)
  • TABLE 286. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2025-2032 (USD MILLION)
  • TABLE 287. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2024 (USD MILLION)
  • TABLE 290. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2025-2032 (USD MILLION)
  • TABLE 291. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 296. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 297. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 298. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 299. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2024 (USD MILLION)
  • TABLE 300. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2025-2032 (USD MILLION)
  • TABLE 301. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2024 (USD MILLION)
  • TABLE 304. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2025-2032 (USD MILLION)
  • TABLE 305. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 309. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 310. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 311. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 312. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 313. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2024 (USD MILLION)
  • TABLE 314. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2025-2032 (USD MILLION)
  • TABLE 315. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2024 (USD MILLION)
  • TABLE 318. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2025-2032 (USD MILLION)
  • TABLE 319. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 320. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 321. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 323. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 324. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 325. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 326. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 327. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2024 (USD MILLION)
  • TABLE 328. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2025-2032 (USD MILLION)
  • TABLE 329. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 330. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 331. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2024 (USD MILLION)
  • TABLE 332. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2025-2032 (USD MILLION)
  • TABLE 333. CANADA DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 334. CANADA DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 335. CANADA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 336. CANADA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 337. CANADA DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)

TABLE 338.